Suppliers and packagers for micardis

micardis

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0040-37	3 BLISTER PACK in 1 CARTON (0597-0040-37) / 10 TABLET in 1 BLISTER PACK	2000-12-01
Boehringer Ingelheim	MICARDIS	telmisartan	TABLET;ORAL	020850	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0041-37	3 BLISTER PACK in 1 CARTON (0597-0041-37) / 10 TABLET in 1 BLISTER PACK	2000-12-01

Micardis Active Pharmaceutical Ingredient Suppliers

Last updated: February 19, 2026

This report details the key suppliers of Telmisartan, the active pharmaceutical ingredient (API) in Micardis. It examines manufacturing capabilities, regulatory compliance, and market presence to inform R&D and investment decisions.

What is Telmisartan and its Therapeutic Use?

Telmisartan is an angiotensin II receptor blocker (ARB) used to treat hypertension, also known as high blood pressure. It works by relaxing blood vessels, which lowers blood pressure and reduces the risk of stroke, heart attack, and kidney problems. Micardis is a brand name for the drug.

Who are the Primary Manufacturers of Telmisartan API?

Several pharmaceutical companies and contract manufacturing organizations (CMOs) specialize in producing Telmisartan API. These entities vary in scale, geographical presence, and regulatory certifications.

Major API Manufacturers and Their Capabilities

Companies actively manufacturing Telmisartan API include:

• Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company with significant API manufacturing capacity. They are known for their backward integration and robust supply chain management. Dr. Reddy's operates multiple FDA-approved facilities and adheres to cGMP standards. Their production volumes for various APIs are proprietary, but they are recognized as a high-volume supplier in the generic API market.

• Aarti Drugs Limited: Another Indian-based pharmaceutical company with a strong focus on API production. Aarti Drugs has a diversified portfolio and exports its products globally. They emphasize quality control and hold certifications from various international regulatory bodies, including EDQM (European Directorate for the Quality of Medicines & HealthCare).

• Granules India Limited: A prominent global pharmaceutical player headquartered in India. Granules India is involved in the manufacturing of APIs, intermediates, and finished dosage forms. They possess advanced manufacturing technologies and a strong regulatory track record, including US FDA and EMA approvals for their facilities.

• Natco Pharma Limited: An integrated Indian pharmaceutical company that manufactures APIs and finished formulations. Natco Pharma has a reputation for developing complex generics and has a strong R&D pipeline. Their API manufacturing sites are designed to meet international quality standards.

• Sun Pharmaceutical Industries Ltd.: One of the world's largest generic pharmaceutical companies, Sun Pharma has extensive API manufacturing capabilities. While they produce a wide range of APIs, their role as a dedicated Telmisartan API supplier is often linked to their internal formulation needs and strategic partnerships. Their facilities are subject to rigorous regulatory oversight from multiple health authorities.

• Lupin Limited: An Indian multinational pharmaceutical company with a substantial API manufacturing footprint. Lupin focuses on quality and compliance, with facilities certified by major global regulatory agencies. They are known for their expertise in various therapeutic areas, including cardiovascular drugs.

• Cadila Healthcare (Zydus Lifesciences): An Indian multinational pharmaceutical company with significant API manufacturing operations. Cadila Healthcare invests heavily in R&D and maintains state-of-the-art manufacturing facilities adhering to stringent international quality standards.

• Huahai Pharmaceutical: A Chinese pharmaceutical company that is a major global supplier of APIs, including ARBs like Telmisartan. Huahai is known for its large-scale production capabilities and has a significant presence in regulated markets, holding US FDA and EMA approvals for its manufacturing sites.

• Divi's Laboratories: An Indian company specializing in the custom synthesis of APIs and intermediates. While Divi's is a major player, their direct public listing of Telmisartan API as a primary product is less pronounced than companies focused on generic finished products. However, they are known for their high-quality manufacturing standards and supply to major pharmaceutical firms.

What are the Regulatory Requirements for Telmisartan API Manufacturing?

Manufacturing Telmisartan API requires adherence to strict regulatory guidelines to ensure product quality, safety, and efficacy. Key regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with Current Good Manufacturing Practices (cGMP) as outlined in 21 CFR Parts 210 and 211. FDA inspections of manufacturing facilities are mandatory, and drug master files (DMFs) must be submitted.

• European Medicines Agency (EMA): Manufacturers exporting to the European Union must meet EU GMP guidelines (EudraLex Volume 4). Compliance is verified through inspections by national competent authorities of EU member states. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often required.

• Pharmaceuticals and Medical Devices Agency (PMDA) - Japan: Manufacturers supplying to Japan must comply with Japanese GMP standards.

• Central Drugs Standard Control Organisation (CDSCO) - India: Domestic manufacturers in India must adhere to CDSCO regulations, which are largely harmonized with international GMP standards.

• Other National Regulatory Authorities: Countries like Canada, Australia, Brazil, and others have their own specific GMP requirements and inspection protocols.

Key Quality Standards and Certifications

• cGMP Compliance: This is the baseline requirement for all API manufacturers supplying regulated markets.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines (e.g., ICH Q7 for API GMP) are critical.
• Pharmacopoeial Standards: APIs must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).
• Drug Master Files (DMFs): A DMF is a submission to a regulatory agency that provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.

What is the Global Market Landscape for Telmisartan API?

The Telmisartan API market is characterized by a significant presence of Indian and Chinese manufacturers, who leverage cost efficiencies and large-scale production capabilities. Key factors influencing the market include generic competition, patent expirations of branded Micardis, and increasing demand for antihypertensive medications globally.

Market Dynamics and Key Players

• Dominance of Generic Manufacturers: With the patent expiry of branded Micardis (Telmisartan), the market has become largely driven by generic API manufacturers. This leads to price competition and a focus on cost-effective production.
• Geographic Supply Hubs: India and China are the primary global hubs for Telmisartan API production, supplying a substantial portion of the world's demand. This is due to their established chemical synthesis infrastructure, skilled labor, and lower manufacturing costs.
• Backward Integration: Larger pharmaceutical companies often engage in backward integration, meaning they produce their own key intermediates or even the API to ensure supply chain security and cost control.
• Contract Manufacturing: Many branded and generic pharmaceutical companies outsource API manufacturing to specialized CMOs to manage production capacity and leverage external expertise.
• Regulatory Scrutiny: Increased regulatory scrutiny from agencies like the FDA and EMA has led to a consolidation in the market, favoring manufacturers with robust quality systems and a strong compliance history.

Competitive Pricing and Supply Chain Considerations

• Price Sensitivity: The generic nature of Telmisartan makes its API market highly price-sensitive. Suppliers compete on cost per kilogram, while maintaining stringent quality standards.
• Supply Chain Reliability: Pharmaceutical companies require reliable and consistent supply of API. Geopolitical factors, trade policies, and natural disasters can impact global supply chains, making diversification of suppliers a strategic imperative.
• Lead Times: Lead times for API procurement can vary significantly depending on the supplier's production schedule, inventory levels, and geographical location.

What are the Technical Specifications for Telmisartan API?

Telmisartan API must meet specific physicochemical and purity standards. These are typically defined by pharmacopoeias and customer specifications.

Critical Quality Attributes

• Assay: The content of Telmisartan in the API, typically specified as not less than 99.0% and not more than 101.0% on the dried basis.
• Related Substances (Impurities): Limits for known and unknown impurities are critical. These include process-related impurities and degradation products. Specific impurities like Telmisartan acid, Telmisartan dimer, and other process intermediates must be controlled within defined limits. For example, individual unspecified impurities are often limited to ≤ 0.10%.
• Water Content: Maximum allowable water content, often determined by Karl Fischer titration (e.g., ≤ 0.5%).
• Residue on Ignition (Sulfated Ash): A measure of inorganic impurities, typically limited to ≤ 0.1%.
• Heavy Metals: Limits for heavy metal contamination, usually ≤ 10 ppm or ≤ 20 ppm.
• Residual Solvents: Limits for residual solvents used during synthesis are defined by ICH Q3C guidelines. Common solvents include methanol, ethanol, isopropanol, toluene, and dichloromethane.
• Particle Size Distribution (PSD): For some formulations, specific particle size ranges are required to ensure dissolution rates and bioavailability. This is a critical parameter for solid dosage forms.
• Polymorphism: Telmisartan can exist in different polymorphic forms, which can affect its solubility, stability, and bioavailability. Manufacturers must control the polymorphic form consistently.

What are the Future Trends in Telmisartan API Supply?

The future of Telmisartan API supply will likely be shaped by several evolving factors:

• Increased Focus on Sustainability: Growing demand for environmentally friendly manufacturing processes and greener chemistry in API production.
• Continuous Manufacturing: Adoption of continuous manufacturing technologies for API production, offering potential benefits in efficiency, quality control, and reduced footprint.
• Supply Chain Resilience: Enhanced efforts to build more resilient and diversified supply chains to mitigate risks from global disruptions.
• Emerging Markets: Growing demand for antihypertensive drugs in emerging economies will drive demand for Telmisartan API.
• Regulatory Harmonization: Continued efforts towards global regulatory harmonization may simplify market access for compliant manufacturers.
• Advanced Analytical Techniques: Greater use of advanced analytical techniques for impurity profiling and characterization to meet ever-increasing quality expectations.

Key Takeaways

• Major Suppliers: Dr. Reddy's Laboratories, Aarti Drugs, Granules India, Natco Pharma, Sun Pharma, Lupin, Cadila Healthcare, and Huahai Pharmaceutical are key Telmisartan API manufacturers.
• Regulatory Imperative: Strict adherence to cGMP, ICH guidelines, and pharmacopoeial standards is mandatory for supplying regulated markets like the US and EU.
• Market Drivers: Generic competition, patent expiries, and global demand for antihypertensives shape the market.
• Quality Specifications: API must meet stringent limits for assay, impurities, water content, and residual solvents.
• Geographic Concentration: India and China are the primary global manufacturing hubs.

Frequently Asked Questions

1. How does the quality of Telmisartan API from different suppliers compare? Quality comparison requires reviewing Certificates of Analysis (CoA), DMFs, and regulatory inspection reports for each supplier. Suppliers with a strong history of FDA/EMA compliance and robust quality management systems are generally considered reliable.

2. What are the typical lead times for ordering Telmisartan API in bulk? Lead times can range from 4 to 12 weeks, depending on the supplier's current production schedule, order volume, and existing inventory. Advance planning is crucial.

3. Are there significant price differences between Telmisartan API sourced from India versus China? While both regions offer competitive pricing, price differences can exist due to varying manufacturing costs, economies of scale, and quality certifications. Direct quotes from multiple suppliers are necessary for accurate comparison.

4. What are the primary challenges in securing a consistent supply of Telmisartan API? Challenges include potential supply chain disruptions (geopolitical, logistical), regulatory changes impacting manufacturing sites, and quality control issues. Diversifying suppliers and building strong relationships can mitigate these risks.

5. What is the significance of Drug Master Files (DMFs) for Telmisartan API? DMFs provide confidential detailed information about the manufacturing process, facilities, and quality controls of the API. They are essential for regulatory submissions by finished dosage form manufacturers, allowing regulatory agencies to review the API's compliance independently.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) in Manufacturing, Processing, Packing, or Holding of Drugs; General. Code of Federal Regulations. Retrieved from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=210.1

[2] European Medicines Agency. (n.d.). EudraLex Volume 4: Good manufacturing practice. Retrieved from https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1999). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from https://www.ema.europa.eu/en/documents/scientific-guideline/ich-harmonised-tripartite-guideline-good-manufacturing-practice-guide-active-pharmaceutical-ingredients_en-0.pdf

[4] United States Pharmacopeia. (n.d.). USP General Chapter <621> Chromatography. United States Pharmacopeia.

[5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificates-suitability-cep

[6] Pharmaceuticals and Medical Devices Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.pmda.go.jp/english/life-science-innovation/post-approval-review/quality-of-drugs/manufacturing-controls/0009.html